Daewoong Pharma seeks to expand Nabota application beyond wrinkle
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Nabota is botulinum toxin product with high purity developed with patented technology, which contains more than 98 percent of the 900 kDa protein known to be the most stable and effective.
In Korea, Nabota is recognized to be effective in cosmetic indications such as improvement of glabellar lines and wrinkles around the eyes, and in the treatment of upper limb muscle stiffness and eyelid spasm after stroke.
The company in April filed a new drug application (NDA) for its use in the treatment of benign masseteric hypertrophy (square jaw) with the Ministry of Food and Drug Safety. In the United States, it has entered a clinical trial to prove its efficacy in migraine and cervical dystonia after winning an approval from the U.S. Food and Drug Administration (FDA).
Currently, various other clinical trials using Nabota also are underway to confirm its efficacy in treatment of male-pattern hair loss, scarless thyroidectomy, treatment of epiphora, improvement in postherpetic neuralgia, sleep bruxism, hot flashes, and etc.
Daewoong Pharmaceutical¡¯s Nabota obtained U.S. FDA approval for its sale in the U.S. market for the first time among Asian botox products and expanded its foothold to 57 countries across the globe. It now is speeding up penetration to Europe and China for this year and next year.
Nabota sales surged 98 percent on year to 30.7 billion won ($24.4 million) in the first quarter of this year. Of them, 22.8 billion won came from exports, soaring 189 percent from a year-ago period. Outlook is much brighter with its upcoming forays into Europe this year, China and Australia next year, and other global markets by 2025.
Daewoong Pharmaceutical in October last year launched its second medical aesthetic lineup V-OLET (deoxycholic acid), an injectable agent to reduce excess jaw fat, and presented how to create synergy with Nabota at various symposiums at home and abroad as part of efforts to expand its presence as a medical aesthetic brand.
Daewoong Pharmaceutical shares were trading 3.22 percent higher at 176,500 won in Seoul trading by midday Friday.
[¨Ï Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Satrec Initiative teams up with Naver for cloud-based satellite imagery service - Pulse by Maeil Business News Korea
- Young South Koreans more insecure about future living conditions than global peers - Pulse by Maeil Business News Korea
- Korean institutional investors to invest $10 mn in Singapore-based biotech firm - Pulse by Maeil Business News Korea
- Kakao found yields his last executive title as Brian Impact Foundation board chair - Pulse by Maeil Business News Korea
- S. Koreans also allowed to join quarantine-free group tours to Japan from June 10 - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- AI가 실시간으로 가격도 바꾼다…아마존·우버 성공 뒤엔 ‘다이내믹 프라이싱’
- 서예지, 12월 29일 데뷔 11년 만에 첫 단독 팬미팅 개최 [공식] - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이